ABT

ABBOTT LABORATORIES

US StockNYSEPharmaceutical Preparations

Research the business. Follow the filings.

Financial information from SEC disclosures, with reporting periods kept in context.

Revenue

44.3B USDAnnual · FY 2025

Operating income

8.1B USDAnnual · FY 2025

Net income

6.5B USDAnnual · FY 2025

Total assets

86.7B USDAnnual · FY 2025

Equity

52.1B USDAnnual · FY 2025

Operating cash flow

9.6B USDAnnual · FY 2025

ABT · Chart

Chart provided by TradingView. Loading the chart connects your browser to TradingView and sends necessary technical information such as your IP address, page URL, and displayed symbol.

TradingView privacy policy

Reported financial information

History varies by metric. Only verified periods are shown; missing periods are not filled in.

Revenue

SEC EDGAR / XBRL · Annual

Selected period · FY 2025

44.3B USD

19 verified periods

2007-12-31 – FY 2025

USD

0B10B20B30B40B50B

12-312007

12-312008

FY2009

FY2010

FY2011

FY2012

FY2013

FY2014

FY2015

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

Scroll horizontally to explore the full history. Select a bar to inspect its value.

Operating income

Source: SEC EDGAR/XBRL

Loading SEC data…

Net income

Source: SEC EDGAR/XBRL

Loading SEC data…